Back to Journals » OncoTargets and Therapy » Volume 5

RETRACTED ARTICLE: Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901

Authors Dan L, Jian D, Na L, Xiaozhong W

Received 24 June 2012

Accepted for publication 13 August 2012

Published 23 October 2012 Volume 2012:5 Pages 271—277

DOI https://doi.org/10.2147/OTT.S35322

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



This paper has been retracted.

Dan L, Jian D, Na L, Xiaozhong W. Onco Targets Ther. 2012;5:271—277.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.

Following publication, a third party raised concerns regarding repeated sections of images in figure 5a that should represent different experimental conditions. Following these concerns being raised, the authors then contacted the journal to request a correction to the figure.

When asked for an explanation regarding the concerns, the authors explained that Figure 5 had been misused. Following an investigation, as verifying the validity of the published work is core to the integrity of the scholarly record, the Editor and Publisher do not believe the concerns can be addressed with a correction, and we are therefore retracting the article. All authors listed in this publication have been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.